Key Points – Liquidia’s YUTREPIA launch is gaining momentum, with first-quarter net product sales rising to $129.9 million, up 44% sequentially from Q4 2025.
The company said it had about 4,500 unique patient prescriptions and roughly 3,750 patients started on therapy since launch. – The company posted its third straight quarter of improving profitability, including net income of $52.9 million and adjusted EBITDA of $71.2 million
Liquidia ended the quarter with $222.8 million in cash, which management said supports continued investment without relying on capital markets. – Management sees a large growth runway in PAH and PH-ILD, with roughly equal prescribing across both markets and expanding use among community physicians. Liquidia is also advancing pipeline efforts, including transition studies for YUTREPIA and the Phase III INSPIRE study of L606. – MarketBeat Week in Review: 12/25 – 12/29 Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. On the company’s earnings call, Chief Executive Officer Roger Jeffs said YUTREPIA has become a leading source of growth in the inhaled prostacyclin category three full quarters after launch.
As of April 30, the company had received approximately 4,500 unique patient prescriptions and started approximately 3,750 patients on therapy since launch, Jeffs said. About 980 physicians have prescribed the therapy since launch. – Liquidia: Court victory the awakening of an industry giant? Jeffs said prescribing has broadened while also becoming deeper among physicians who have already used the product.